GI View has been granted ISO 13485:2003 certification of its quality system, and received CE Marking for its Aer-O-Scope™ device. The Company expects to file a 510(k) with the FDA and to launch the Aer-O-Scope™ commercially by the second half of 2008.
September 2006
GI View featured on the '10 most promising Startups of 2006' ranking conducted by Globes, the Israeli Business Newspaper
February 2006
GI View conducted another human trial on healthy volunteers in which the omni camera was used for the first time in humans. The 360 degree viewing of the inner surface of the colon proved to be as expected.
June 2005
G.I. View second feasibility clinical study to evaluate the motion mechanism of the Aer-O-Scope™ traveling through the colon in healthy volunteers was completed with excellent safety and performance results.
The first phase feasibility clinical study to evaluate the motion mechanism of the Aer-O-Scope™ traveling through the colon in healthy volunteers was completed with impressive result. Additional trial is planned for Q3 2005.
G.I. View has completed a $7M financing round. Israel Healthcare Ventures led the round and was joined by Delta Ventures and all previous private investors.
October 2004
G.I. View has completed the first Aer-O-Scope™ in vivo study on porcine model.